NCT05357196 - PT-112 (Phosplatin's Platinum) Combine With Gemcitabine Injection for Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2020

Primary Completion Date

August 30, 2022

Study Completion Date

April 28, 2023

Conditions

Biliary Tract Cancer

Interventions

DRUG

PT-112

"Drug: PT-112, The MTD(Maximum Tolerated Dose ) and RP2D of PT-112 when used in combination with gemcitabine will be determined during dose escalation.~Drug: Gemcitabine, Gemcitabine will be administered at a fixed dose of 1000 mg."

Trial Locations (4)

200032

RECRUITING

Zhongshan Hospital Fudan Universtity, Shanghai

210002

NOT_YET_RECRUITING

General Hospital Of Eastern Theater Command, Nanjing

310003

RECRUITING

The First Affiliated Hospital ZheJiang University School Of Medicine, Hangzhou

430071

RECRUITING

ZhongNan Hospital Of Wuhan University, Wuhan